TY - JOUR T1 - BNT162b2 boosted immune responses six months after heterologous or homologous ChAdOx1nCoV-19/BNT162b2 vaccination against COVID-19 JF - medRxiv DO - 10.1101/2021.12.25.21268392 SP - 2021.12.25.21268392 AU - Georg M. N. Behrens AU - Joana Barros-Martins AU - Anne Cossmann AU - Gema Morillas Ramos AU - Metodi V. Stankov AU - Ivan Odak AU - Alexandra Dopfer-Jablonka AU - Laura Hetzel AU - Miriam Köhler AU - Gwendolyn Patzer AU - Christoph Binz AU - Christiane Ritter AU - Michaela Friedrichsen AU - Christian Schultze-Florey AU - Inga Ravens AU - Stefanie Willenzon AU - Anja Bubke AU - Jasmin Ristenpart AU - Anika Janssen AU - George Ssebyatika AU - Günter Bernhardt AU - Markus Hoffmann AU - Stefan Pöhlmann AU - Thomas Krey AU - Berislav Bošnjak AU - Swantje I. Hammerschmidt AU - Reinhold Förster Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/12/27/2021.12.25.21268392.abstract N2 - Reports suggest that COVID-19 vaccine effectiveness is decreasing, either due to waning immune protection, emergence of new variants of concern, or both. Heterologous prime/boost vaccination with a vector-based approach (ChAdOx-1nCov-19, ChAd) followed by an mRNA vaccine (e.g. BNT162b2, BNT) appeared to be superior in inducing protective immunity, and large scale second booster vaccination is ongoing. However, data comparing declining immunity after homologous and heterologous vaccination as well as effects of a third vaccine application after heterologous ChAd/BNT vaccination are lacking. We longitudinally monitored immunity in ChAd/ChAd (n=41) and ChAd/BNT (n=88) vaccinated individuals and assessed the impact of a second booster with BNT in both groups. The second booster greatly augmented waning anti-spike IgG but only moderately increased spike-specific CD4+ and CD8+ T cells in both groups to cell frequencies already present after the boost. More importantly, the second booster efficiently restored neutralizing antibody responses against Alpha, Beta, Gamma, and Delta, but neutralizing activity against B.1.1.529 (Omicron) stayed severely impaired. Our data suggest that inferior SARS-CoV-2 specific immune responses after homologous ChAd/ChAd vaccination can be cured by a heterologous BNT vaccination. However, prior heterologous ChAd/BNT vaccination provides no additional benefit for spike-specific T cell immunity or neutralizing Omicron after the second boost.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the German Center for Infection Research TTU 01.938 (grant no 80018019238 to G.M.N.B and R.F.), and TTU 04.820 to G.M.N.B., by Deutsche Forschungsgemeinschaft, (DFG, German Research Foundation) Excellence Strategy EXC 2155 RESIST (Project ID39087428 to R.F.), by funds of the State of Lower Saxony (14-76103-184 CORONA-11/20 to R.F.), by funds of the BMBF (NaFoUniMedCovid19 FKZ: 01KX2021; Projects B-FAST to R.F.) and Deutsche Forschungsgemeinschaft, SFB 900/3 (Projects B1, 158989968 to R.F.), and the European Regional Development Fund (Defeat Corona, ZW7-8515131 and ZW7-85151373 to G.M.N.B.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The CoCo Study and the analysis conducted for this article were approved by the Internal Review Board of Hannover Medical School (institutional review board no. 8973_BO-K_2020, amendment Dec 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -